ASPIRE trial explores survival benefits of adding chemotherapy to standard prostate cancer treatment

The Alliance for Clinical Trials in Oncology is now enrolling patients in the ASPIRE trial (A032302)-a large-scale, phase III clinical study investigating whether adding chemotherapy to current standard treatments extends survival for men with advanced prostate cancer.